Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
Real-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients With Chorea Associated With Huntington's Disease.
The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
The Secondary Objectives: To evaluate the real-world safety of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 4단계
연락처 및 위치
연구 장소
-
-
-
Beijing, 중국, 100053
- Teva Investigational Site 03
-
Beijing, 중국, 100070
- Teva Investigational Site 02
-
Chengdu, 중국, 610041
- Teva Investigational Site 01
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Participants with clinically confirmed diagnosis of chorea associated with Huntington's Disease (HD)
- Participants whose baseline total maximal chorea (TMC) score ≥ 8
- Participants who are deutetrabenazine-naïve before study entry or who did not receive deutetrabenazine within 30 days of study entry, and who are about to be treated with deutetrabenazine for chorea associated with HD
- Participants who have provided written consent for the use of personal and medical information for study purposes
Exclusion Criteria:
- Participants who have an unstable or serious medical or psychiatric illness at baseline
- Participants with any history of suicidality, untreated or inadequately treated depression
- Participants with certain comorbidities, including hepatic impairment, congenital long QT syndrome, and clinically significant cardiac arrhythmias.
- Participants who received reserpine within 20 days of deutetrabenazine treatment initiation
- Participants who received monoamine oxidase inhibitors within 14 days of deutetrabenazine treatment initiation
- Participants who received vesicular monoamine transporter 2 (VMAT2) inhibitors, e.g., tetrabenazine or valbenazine, within 30 days of deutetrabenazine treatment initiation
- Participants unable to provide a written consent for the study.
- Participants who are participating in another study that includes treatment with an investigational drug and/or intervention at the same time as enrolment in the current study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Deutetrabenazine
|
deutetrabenazine tablets
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change From Baseline in TMC Score in Participants Receiving ≥24 mg/Day
기간: Baseline, Week 16
|
The TMC score was determined from Item 12 of the motor assessment (Part 1) of the UHDRS and quantifies chorea (range, 0-28, lower score indicated less chorea).
It was the sum of maximal chorea scores for 7 body regions (face, buccal-oral-lingual, trunk, and 4 extremities), each of which was scored on a scale from 0 to 4 (0, absent; 1, slight or intermittent; 2, mild and common or moderate and intermittent; 3, moderate and common; and 4, marked and prolonged).
|
Baseline, Week 16
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants With Any Adverse Events (AEs) By Severity Grade
기간: Baseline up to Week 16
|
AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Severity of AEs recorded as one of following Common Terminology Criteria for Adverse Events (CTCAE) criteria: -Grade 1: Mild; asymptomatic or mild symptoms; clinical/diagnostic observations only; intervention not indicated.
-Grade 2: Moderate; local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL) (for example, preparing meals, shopping for groceries or clothes, using telephone).
-Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization; disabling; limiting self-care ADL (bathing, dressing, feeding self, using toilet, taking medications, and not bedridden).
-Grade 4: Life-threatening; urgent intervention indicated.
-Grade 5: Death related to AE.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With Serious Adverse Events (SAEs)
기간: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
The SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With Treatment-related AEs
기간: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Number of participants with treatment-related AEs is reported in this outcome measure.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With AEs Leading to Dose Reduction, Interruption, Treatment Discontinuation, and Study Withdrawal
기간: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Number of participants with AEs leading to dose reduction, interruption, treatment discontinuation, and study withdrawal is reported in this outcome measure.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With AEs in Titration Phase
기간: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
AEs lasted from titration phase to maintenance phase were considered an AE that occurred in the titration phase.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With AEs in Maintenance Phase
기간: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With AEs of Special Interest
기간: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
AEs of special interest included suicidality, depression, somnolence, QTc prolongation, akathisia, and parkinsonism.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Change From Baseline in TMC Score in All Participants Regardless of Study Drug Dose
기간: Baseline, Week 16
|
The TMC score was determined from Item 12 of the motor assessment (Part 1) of the UHDRS and quantifies chorea (range, 0-28, lower score indicated less chorea).
It was the sum of maximal chorea scores for 7 body regions (face, buccal-oral-lingual, trunk, and 4 extremities), each of which was scored on a scale from 0 to 4 (0, absent; 1, slight or intermittent; 2, mild and common or moderate and intermittent; 3, moderate and common; and 4, marked and prolonged).
|
Baseline, Week 16
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Teva Medical Expert, MD, Teva Branded Pharmaceutical Products R&D LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- TV50717-NDG-40182
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .